Pan American Silver Corp. Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? Pan American Silver Corp. Common Stock trades at $43.24 (market cap $17.55B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: Pan American Silver Corp. Common Stock is far larger — about 12.1× uniQure N.V. Ordinary Shares's market cap, and Pan American Silver Corp. Common Stock pays a 1.74% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pan American Silver Corp. Common Stock for 2 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| PAAS | QURE | |
|---|---|---|
Market Cap | $17.55B | $1.45B |
Volume | 6,423,301 | 3,323,243 |
Sector | Basic Materials | Health |
52-Week High | $68.70 | $70.59 |
52-Week Low | $33.20 | $9.03 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $16.69B | $707.46M |
Dividend Yield | 1.74% | — |
Signals from Pluang's Aura AI — not financial advice
Pan American Silver (PAAS) trades at $44.53, down 2.58% on the day, with a bearish technical signal from moving averages. The company reported strong 2025 results with $978M net income and a 32.03% net margin, and analysts project 2026 revenue growth to $4.3B. Recent news highlights growth from the Timmins and La Colorada projects and a director retirement effective October 31, 2026.
The outlook is positive with a consensus price target of $62.50, implying 40% upside, supported by solid cash flow and reserve growth. Risks include silver price volatility and potential cost pressures. Analyst sentiment is bullish with 52% buy ratings, but technical indicators suggest near-term caution.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Pan American Silver is a mining company focused on silver and gold production in the Americas. It also explores and develops precious metals properties.
Read more on PAAS →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →